Physician profile
Arthur O Romero
NPI 1669631743
$310,415.02
in general payments reported to CMS, 2019-2025
25 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $803 · 2021: $9,869 · 2022: $4,777 · 2023: $85K · 2024: $102K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $224K · Travel and Lodging: $48K · Food and Beverage: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $224,322.52 |
| Travel and Lodging | $47,630.32 |
| Food and Beverage | $19,587.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $296,727.97 | 2019-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $4,553.12 | 2021-2025 | Breztri, Tagrisso, Airsupra |
| Pulmonx Corporation | $3,108.36 | 2020-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Boston Scientific Corporation | $1,278.22 | 2019-2022 | |
| Pinnacle Biologics, INC | $1,167.65 | 2019 | |
| Steris Corporation | $956.48 | 2025 | |
| Olympus Corporation of The Americas | $746.49 | 2024 | Spiration Valve System, Single Use Suction Valve (Sterile) |
| Ethicon INC. | $740.01 | 2021 | |
| Mylan Specialty L.P. | $238.18 | 2023-2024 | Yupelri |
| Olympus America INC. | $222.17 | 2023-2025 | Spiration Valve System |
| Genzyme Corporation | $174.09 | 2024-2025 | |
| Cook Medical LLC | $82.76 | 2019 | |
| Veran Medical Technologies, INC. | $72.57 | 2021 | |
| Merit Medical Systems INC | $69.00 | 2023 | Aeromini Stent and Delivery System, Aero Stent and Delivery System |
| Inogen, INC. | $58.68 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.85 | 2023 | Tezspire |
| Viatris Specialty LLC | $35.08 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $27.19 | 2022-2023 | Acthar |
| Insmed, INC. | $25.48 | 2024 | Arikayce |
| Philips North America LLC | $19.22 | 2019 | |
| Chiesi USA, INC. | $17.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.48 | 2023 | Ofev |
| Medtronic, INC. | $16.74 | 2022 | |
| Glaxosmithkline, LLC. | $13.72 | 2025 | Nucala |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Romero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.